Seelos Therapeutics Navigates Financial and Board Changes

Seelos Therapeutics (SEEL) just unveiled an update.

Seelos Therapeutics, Inc. has amended its Convertible Promissory Note with Lind Global Asset Management, adjusting financial requirements and payment terms, amidst a strategic shift towards mental health initiatives that included workforce reductions and cost-saving measures. Despite these changes, the company faces delisting from the Nasdaq Capital Market for not meeting minimum bid price and market value requirements, and is considering options like a reverse stock split to regain compliance. Meanwhile, board member Daniel J. O’Connor has resigned for personal reasons, with no disagreements cited regarding company operations.

For a thorough assessment of SEEL stock, go to TipRanks’ Stock Analysis page.